Inhibitors of diacylglycerol kinase, particularly diacylglycerol kinase α (DGK-α, DGKA) and/or diacylglycerol kinase ζ (DGK-ζ, DGKZ), believed to be useful for the treatment of cancer and viral infections, have been disclosed by Inventisbio Co. Ltd. and Inventisbio LLC.
Several Insilico Medicine Inc. patents describe diacylglycerol kinase α (DGK-α, DGKA) inhibitors reported to be useful for the treatment of cancer and viral infection.
Arvinas Operations Inc. has reported the development of diacylglycerol kinase α (DGK-α; DGKA) inhibitors reported to be useful for the treatment of cancer.
A Gossamer Bio Inc. patent describes oxime derivatives that act as diacylglycerol kinase α (DGKA) and/or diacylglycerol kinase ζ (DGKZ) inhibitors and are thus reported to be useful for the treatment of cancer and viral infections.
